We have previously shown that CC3 immunostaining of treated tumor sections is a reliable biomarker of ZMC1 activity using a pharmacodynamics experiment in which mice were administered three doses of ZMC1 over 3 days and the tumors were harvested.25 CC3 staining was greater in ZMC1 treated Brca1−/−;Trp53R172H/− tumors than Brca1−/−;Trp53−/− tumors indicating an on target effect of ZMC1. The gene discussed is TP53; the disease is neoplasm.